<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059825</url>
  </required_header>
  <id_info>
    <org_study_id>8835-016</org_study_id>
    <secondary_id>B1521006</secondary_id>
    <secondary_id>2009-017131-18</secondary_id>
    <nct_id>NCT01059825</nct_id>
  </id_info>
  <brief_title>Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)</brief_title>
  <official_title>A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational
      drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus.
      Participants in the study will receive 1 of 6 treatments for 12 weeks including 1 treatment
      with an approved drug (sitagliptin) for the treatment of Type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 24, 2010</start_date>
  <completion_date type="Actual">January 20, 2011</completion_date>
  <primary_completion_date type="Actual">January 20, 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline</time_frame>
    <description>HbA1c is measured as percent.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward [LOCF]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1C at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Body Weight</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The percent change from baseline is the ([Week 12 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The percent change from baseline is the ([Week 2 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The percent change from baseline is the ([Week 4 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Body Weight at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The percent change from baseline is the ([Week 8 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Systolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Diastolic Blood Pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Fasting Plasma Glucose</measure>
    <time_frame>Baseline</time_frame>
    <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 2</measure>
    <time_frame>Baseline and Week 2</time_frame>
    <description>The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
    <description>The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1c &lt;7% at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving HbA1C &lt;6.5% at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Advere Event (AE)</measure>
    <time_frame>Up to 98 days</time_frame>
    <description>An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Medication Due to an AE</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">375</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ertugliflozin</intervention_name>
    <description>Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 1 mg</intervention_name>
    <description>Tablet, 1 mg, once daily for 84 days</description>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 5 mg</intervention_name>
    <description>Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days</description>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin 25 mg</intervention_name>
    <description>Tablet, 25 mg, once daily for 84 days</description>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100 mg</intervention_name>
    <description>Tablet, 100 mg, once daily for 84 days</description>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Januvia®, Tesavel®, Xelevia®, Ristaben®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Sitagliptin</intervention_name>
    <description>Tablet, matching placebo to 100 mg, once daily for 84 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ertugliflozin 1 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 5 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 10 mg</arm_group_label>
    <arm_group_label>Ertugliflozin 25 mg</arm_group_label>
    <arm_group_label>Sitagliptin 100 mg</arm_group_label>
    <other_name>Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with type 2 diabetes on stable doses of background medicines for
             management of the diabetes; aged 18-70 years; body mass index between 23-45 kg/m^2

        Exclusion Criteria:

          -  Participants with type 1 diabetes, heart attack or stroke in last 6-months,
             uncontrolled blood pressure, significant kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Amin NB, Wang X, Jain SM, Lee DS, Nucci G, Rusnak JM. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015 Jun;17(6):591-8. doi: 10.1111/dom.12460. Epub 2015 Mar 31.</citation>
    <PMID>25754396</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <results_first_submitted>September 8, 2017</results_first_submitted>
  <results_first_submitted_qc>September 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2017</results_first_posted>
  <disposition_first_submitted>November 12, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 12, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 19, 2012</disposition_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2</keyword>
  <keyword>safety and efficacy study with ertugliflozin (PF-04971729, MK-8835)</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of the 375 enrolled participants included in the metformin run-in period, 328 participants were randomized to 1 of 6 treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="P2">
          <title>Ertugliflozin 1 mg</title>
          <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="P3">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="P4">
          <title>Ertugliflozin 10 mg</title>
          <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="P5">
          <title>Ertugliflozin 25 mg</title>
          <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="P6">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
        </group>
        <group group_id="P7">
          <title>Metformin Run-in</title>
          <description>Participants received open-label metformin during the run-in period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrolled, Run-in Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="375"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="328"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse event not related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54">54 participants who completed the run-in period were randomized to this treatment group.</participants>
                <participants group_id="P2" count="54">54 participants who completed the run-in period were randomized to this treatment group.</participants>
                <participants group_id="P3" count="55">55 participants who completed the run-in period were randomized to this treatment group.</participants>
                <participants group_id="P4" count="55">55 participants who completed the run-in period were randomized to this treatment group.</participants>
                <participants group_id="P5" count="55">55 participants who completed the run-in period were randomized to this treatment group.</participants>
                <participants group_id="P6" count="55">55 participants who completed the run-in period were randomized to this treatment group.</participants>
                <participants group_id="P7" count="0">Participants who completed run-in were randomized to 1 of 6 treatment groups.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="49"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="52"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient clinical response</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event not related to study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 375 enrolled participants included in the metformin run-in period, 328 participants were randomized to 1 of 6 treatment groups.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="B2">
          <title>Ertugliflozin 1 mg</title>
          <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="B3">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="B4">
          <title>Ertugliflozin 10 mg</title>
          <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="B5">
          <title>Ertugliflozin 25 mg</title>
          <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="B6">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="55"/>
            <count group_id="B4" value="55"/>
            <count group_id="B5" value="55"/>
            <count group_id="B6" value="55"/>
            <count group_id="B7" value="328"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="47"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="40"/>
                    <measurement group_id="B7" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline Hemoglobin A1c (HbA1c)</title>
        <description>HbA1c is measured as percent.</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Hemoglobin A1c (HbA1c)</title>
          <description>HbA1c is measured as percent.</description>
          <population>All randomized participants.</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.08" spread="0.14"/>
                    <measurement group_id="O2" value="8.01" spread="0.17"/>
                    <measurement group_id="O3" value="7.88" spread="0.13"/>
                    <measurement group_id="O4" value="8.13" spread="0.17"/>
                    <measurement group_id="O5" value="8.30" spread="0.16"/>
                    <measurement group_id="O6" value="8.24" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c at Week 12</title>
        <description>HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward [LOCF]).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 12</title>
          <description>HbA1c is measured as percent. The change from baseline is the Week 12 HbA1c percent minus the Week 0 HbA1c percent (last observation carried forward [LOCF]).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 12.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" lower_limit="-0.25" upper_limit="0.04"/>
                    <measurement group_id="O2" value="-0.56" lower_limit="-0.69" upper_limit="-0.42"/>
                    <measurement group_id="O3" value="-0.80" lower_limit="-0.94" upper_limit="-0.66"/>
                    <measurement group_id="O4" value="-0.73" lower_limit="-0.87" upper_limit="-0.58"/>
                    <measurement group_id="O5" value="-0.83" lower_limit="-0.98" upper_limit="-0.69"/>
                    <measurement group_id="O6" value="-0.87" lower_limit="-1.01" upper_limit="-0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference between ertugliflozin and placebo on the primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.72</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1C at Week 2</title>
        <description>HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1C at Week 2</title>
          <description>HbA1c is measured as percent. The change from baseline is the Week 2 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 2.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.08" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.21" upper_limit="-0.06"/>
                    <measurement group_id="O3" value="-0.29" lower_limit="-0.36" upper_limit="-0.21"/>
                    <measurement group_id="O4" value="-0.22" lower_limit="-0.29" upper_limit="-0.15"/>
                    <measurement group_id="O5" value="-0.17" lower_limit="-0.25" upper_limit="-0.10"/>
                    <measurement group_id="O6" value="-0.26" lower_limit="-0.33" upper_limit="-0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Week 4</title>
        <description>HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 4</title>
          <description>HbA1c is measured as percent. The change from baseline is the Week 4 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 4.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.13" upper_limit="0.06"/>
                    <measurement group_id="O2" value="-0.40" lower_limit="-0.50" upper_limit="-0.31"/>
                    <measurement group_id="O3" value="-0.49" lower_limit="-0.59" upper_limit="-0.40"/>
                    <measurement group_id="O4" value="-0.48" lower_limit="-0.57" upper_limit="-0.38"/>
                    <measurement group_id="O5" value="-0.40" lower_limit="-0.49" upper_limit="-0.30"/>
                    <measurement group_id="O6" value="-0.48" lower_limit="-0.57" upper_limit="-0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>-0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c at Week 8</title>
        <description>HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c at Week 8</title>
          <description>HbA1c is measured as percent. The change from baseline is the Week 8 HbA1c percent minus the Week 0 HbA1c percent (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline HbA1c measurement and at least 1 post-baseline HbA1c measurement up to Week 8.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-0.22" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-0.69" upper_limit="-0.45"/>
                    <measurement group_id="O3" value="-0.76" lower_limit="-0.88" upper_limit="-0.64"/>
                    <measurement group_id="O4" value="-0.73" lower_limit="-0.85" upper_limit="-0.60"/>
                    <measurement group_id="O5" value="-0.75" lower_limit="-0.87" upper_limit="-0.62"/>
                    <measurement group_id="O6" value="-0.77" lower_limit="-0.89" upper_limit="-0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>-0.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.63</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>-0.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>-0.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.67</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Body Weight</title>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Body Weight</title>
          <population>All randomized participants.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.78" spread="2.37"/>
                    <measurement group_id="O2" value="83.44" spread="2.57"/>
                    <measurement group_id="O3" value="85.74" spread="2.82"/>
                    <measurement group_id="O4" value="82.28" spread="2.93"/>
                    <measurement group_id="O5" value="81.81" spread="2.34"/>
                    <measurement group_id="O6" value="85.52" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Body Weight at Week 12</title>
        <description>The percent change from baseline is the ([Week 12 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight at Week 12</title>
          <description>The percent change from baseline is the ([Week 12 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 12.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" lower_limit="-1.18" upper_limit="-0.32"/>
                    <measurement group_id="O2" value="-1.90" lower_limit="-2.32" upper_limit="-1.48"/>
                    <measurement group_id="O3" value="-2.50" lower_limit="-2.92" upper_limit="-2.07"/>
                    <measurement group_id="O4" value="-2.90" lower_limit="-3.33" upper_limit="-2.47"/>
                    <measurement group_id="O5" value="-2.66" lower_limit="-3.10" upper_limit="-2.23"/>
                    <measurement group_id="O6" value="-0.30" lower_limit="-0.72" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.15</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.75</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.75</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.35</ci_lower_limit>
            <ci_upper_limit>-1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.15</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.76</ci_lower_limit>
            <ci_upper_limit>-1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.91</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.833</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.45</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Body Weight at Week 2</title>
        <description>The percent change from baseline is the ([Week 2 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight at Week 2</title>
          <description>The percent change from baseline is the ([Week 2 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 2.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" lower_limit="-0.46" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-0.65" lower_limit="-0.87" upper_limit="-0.44"/>
                    <measurement group_id="O3" value="-1.36" lower_limit="-1.59" upper_limit="-1.14"/>
                    <measurement group_id="O4" value="-1.14" lower_limit="-1.36" upper_limit="-0.92"/>
                    <measurement group_id="O5" value="-1.11" lower_limit="-1.33" upper_limit="-0.88"/>
                    <measurement group_id="O6" value="0.21" lower_limit="-0.01" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.13</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.44</ci_lower_limit>
            <ci_upper_limit>-0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.22</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.967</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.45</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.14</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Body Weight at Week 4</title>
        <description>The percent change from baseline is the ([Week 4 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight at Week 4</title>
          <description>The percent change from baseline is the ([Week 4 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 4.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" lower_limit="-0.73" upper_limit="-0.15"/>
                    <measurement group_id="O2" value="-1.20" lower_limit="-1.48" upper_limit="-0.92"/>
                    <measurement group_id="O3" value="-1.76" lower_limit="-2.04" upper_limit="-1.48"/>
                    <measurement group_id="O4" value="-1.68" lower_limit="-1.97" upper_limit="-1.39"/>
                    <measurement group_id="O5" value="-1.52" lower_limit="-1.81" upper_limit="-1.23"/>
                    <measurement group_id="O6" value="0.01" lower_limit="-0.28" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.32</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.73</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.24</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>-0.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward..</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>-1.08</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>-0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.922</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.45</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Body Weight at Week 8</title>
        <description>The percent change from baseline is the ([Week 8 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Body Weight at Week 8</title>
          <description>The percent change from baseline is the ([Week 8 body weight minus the Week 0 body weight] divided by the Week 0 body weight) X 100 (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline body weight measurement and at least 1 post-baseline body weight measurement up to Week 8.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-0.96" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-1.65" lower_limit="-1.98" upper_limit="-1.32"/>
                    <measurement group_id="O3" value="-2.18" lower_limit="-2.52" upper_limit="-1.85"/>
                    <measurement group_id="O4" value="-2.30" lower_limit="-2.64" upper_limit="-1.96"/>
                    <measurement group_id="O5" value="-2.40" lower_limit="-2.74" upper_limit="-2.06"/>
                    <measurement group_id="O6" value="-0.38" lower_limit="-0.71" upper_limit="-0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.03</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.04</ci_lower_limit>
            <ci_upper_limit>-1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.68</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.16</ci_lower_limit>
            <ci_upper_limit>-1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.78</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.26</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.741</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.24</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Systolic Blood Pressure</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Systolic Blood Pressure</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.</description>
          <population>All randomized participants.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.7" spread="1.71"/>
                    <measurement group_id="O2" value="126.5" spread="2.18"/>
                    <measurement group_id="O3" value="127.9" spread="2.31"/>
                    <measurement group_id="O4" value="125.8" spread="1.97"/>
                    <measurement group_id="O5" value="124.9" spread="2.20"/>
                    <measurement group_id="O6" value="126.6" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 12</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 12</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 12.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" lower_limit="-2.55" upper_limit="1.44"/>
                    <measurement group_id="O2" value="-2.69" lower_limit="-4.63" upper_limit="-0.75"/>
                    <measurement group_id="O3" value="-4.03" lower_limit="-5.99" upper_limit="-2.07"/>
                    <measurement group_id="O4" value="-3.43" lower_limit="-5.43" upper_limit="-1.43"/>
                    <measurement group_id="O5" value="-3.93" lower_limit="-5.94" upper_limit="-1.91"/>
                    <measurement group_id="O6" value="-1.09" lower_limit="-3.05" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.163</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.13</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.92</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.48</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.28</ci_lower_limit>
            <ci_upper_limit>-0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.88</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.70</ci_lower_limit>
            <ci_upper_limit>-0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.37</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.21</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.403</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.54</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.33</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 2</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 2</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 2.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" lower_limit="-3.73" upper_limit="-0.12"/>
                    <measurement group_id="O2" value="-2.30" lower_limit="-4.08" upper_limit="-0.51"/>
                    <measurement group_id="O3" value="-4.73" lower_limit="-6.57" upper_limit="-2.89"/>
                    <measurement group_id="O4" value="-2.28" lower_limit="-4.10" upper_limit="-0.45"/>
                    <measurement group_id="O5" value="-5.39" lower_limit="-7.23" upper_limit="-3.55"/>
                    <measurement group_id="O6" value="-0.91" lower_limit="-2.74" upper_limit="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.425</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.91</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.082</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.81</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.38</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.430</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.92</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.043</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.47</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.05</ci_lower_limit>
            <ci_upper_limit>-0.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.694</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>1.01</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.55</ci_lower_limit>
            <ci_upper_limit>3.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 4</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 4</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 4.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" lower_limit="-4.31" upper_limit="-0.82"/>
                    <measurement group_id="O2" value="-3.94" lower_limit="-5.64" upper_limit="-2.25"/>
                    <measurement group_id="O3" value="-5.15" lower_limit="-6.86" upper_limit="-3.44"/>
                    <measurement group_id="O4" value="-5.43" lower_limit="-7.17" upper_limit="-3.69"/>
                    <measurement group_id="O5" value="-3.33" lower_limit="-5.09" upper_limit="-1.57"/>
                    <measurement group_id="O6" value="-3.32" lower_limit="-5.05" upper_limit="-1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.38</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.81</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.087</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.59</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.03</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.86</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.33</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.346</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.77</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.25</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.346</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.21</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Systolic Blood Pressure at Week 8</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure at Week 8</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 systolic blood pressure minus the Week 0 systolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline systolic blood pressure measurement and at least 1 post-baseline systolic blood pressure measurement up to Week 8.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" lower_limit="-2.42" upper_limit="1.55"/>
                    <measurement group_id="O2" value="-1.53" lower_limit="-3.46" upper_limit="0.40"/>
                    <measurement group_id="O3" value="-2.85" lower_limit="-4.80" upper_limit="-0.90"/>
                    <measurement group_id="O4" value="-3.04" lower_limit="-5.03" upper_limit="-1.06"/>
                    <measurement group_id="O5" value="-3.30" lower_limit="-5.31" upper_limit="-1.30"/>
                    <measurement group_id="O6" value="-2.43" lower_limit="-4.38" upper_limit="-0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.10</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.87</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.41</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.19</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.117</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.61</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.42</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.097</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.87</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.69</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.179</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.00</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Diastolic Blood Pressure</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Diastolic Blood Pressure</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed.</description>
          <population>All randomized participants.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.14" spread="1.24"/>
                    <measurement group_id="O2" value="78.95" spread="1.14"/>
                    <measurement group_id="O3" value="78.19" spread="1.36"/>
                    <measurement group_id="O4" value="78.45" spread="1.32"/>
                    <measurement group_id="O5" value="78.61" spread="1.24"/>
                    <measurement group_id="O6" value="79.15" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 12</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 12</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 12 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 12.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="-0.41" upper_limit="2.02"/>
                    <measurement group_id="O2" value="-1.12" lower_limit="-2.30" upper_limit="0.06"/>
                    <measurement group_id="O3" value="-1.01" lower_limit="-2.20" upper_limit="0.18"/>
                    <measurement group_id="O4" value="-3.18" lower_limit="-4.40" upper_limit="-1.97"/>
                    <measurement group_id="O5" value="-1.83" lower_limit="-3.06" upper_limit="-0.61"/>
                    <measurement group_id="O6" value="1.68" lower_limit="0.49" upper_limit="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.93</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.62</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.086</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.81</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.51</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.99</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.71</ci_lower_limit>
            <ci_upper_limit>-2.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.64</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.37</ci_lower_limit>
            <ci_upper_limit>-0.92</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.746</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.88</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 2</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 2</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 2 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 2.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" lower_limit="-1.69" upper_limit="0.56"/>
                    <measurement group_id="O2" value="-1.25" lower_limit="-2.37" upper_limit="-0.14"/>
                    <measurement group_id="O3" value="-1.26" lower_limit="-2.41" upper_limit="-0.12"/>
                    <measurement group_id="O4" value="-1.97" lower_limit="-3.11" upper_limit="-0.84"/>
                    <measurement group_id="O5" value="-3.01" lower_limit="-4.16" upper_limit="-1.86"/>
                    <measurement group_id="O6" value="0.92" lower_limit="-0.22" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.289</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.69</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.288</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.70</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.31</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.130</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.41</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.01</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.44</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.05</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.883</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>1.49</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>3.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 4</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 4</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 4 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 4.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" lower_limit="-1.80" upper_limit="0.21"/>
                    <measurement group_id="O2" value="-2.47" lower_limit="-3.44" upper_limit="-1.49"/>
                    <measurement group_id="O3" value="-3.08" lower_limit="-4.07" upper_limit="-2.10"/>
                    <measurement group_id="O4" value="-2.81" lower_limit="-3.81" upper_limit="-1.80"/>
                    <measurement group_id="O5" value="-2.10" lower_limit="-3.11" upper_limit="-1.09"/>
                    <measurement group_id="O6" value="-0.51" lower_limit="-1.51" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.063</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.67</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.07</ci_lower_limit>
            <ci_upper_limit>-0.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.29</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.69</ci_lower_limit>
            <ci_upper_limit>-0.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.01</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.43</ci_lower_limit>
            <ci_upper_limit>-0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.121</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.30</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.73</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>0.29</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.13</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Diastolic Blood Pressure at Week 8</title>
        <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure at Week 8</title>
          <description>Sitting blood pressure was measured in triplicate and the average of the measurements taken at a single assessment time was analyzed. The change from baseline is the Week 8 diastolic blood pressure minus the Week 0 diastolic blood pressure (LOCF).</description>
          <population>Analysis population included randomized participants who were treated, had a baseline diastolic blood pressure measurement and at least 1 post-baseline diastolic blood pressure measurement up to Week 8.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" lower_limit="-0.40" upper_limit="1.99"/>
                    <measurement group_id="O2" value="-1.40" lower_limit="-2.56" upper_limit="-0.24"/>
                    <measurement group_id="O3" value="-0.69" lower_limit="-1.86" upper_limit="0.48"/>
                    <measurement group_id="O4" value="-2.23" lower_limit="-3.42" upper_limit="-1.04"/>
                    <measurement group_id="O5" value="-1.20" lower_limit="-2.40" upper_limit="0.01"/>
                    <measurement group_id="O6" value="0.32" lower_limit="-0.85" upper_limit="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.045</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-2.20</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.86</ci_lower_limit>
            <ci_upper_limit>-0.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.126</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.49</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.16</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-3.03</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.72</ci_lower_limit>
            <ci_upper_limit>-1.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-1.99</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.69</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.357</p_value>
            <p_value_desc>P-value is one-sided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.15</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Fasting Plasma Glucose</title>
        <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
        <time_frame>Baseline</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Fasting Plasma Glucose</title>
          <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
          <population>All randomized participants.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.3" spread="5.65"/>
                    <measurement group_id="O2" value="162.5" spread="6.75"/>
                    <measurement group_id="O3" value="156.5" spread="5.79"/>
                    <measurement group_id="O4" value="163.3" spread="6.30"/>
                    <measurement group_id="O5" value="171.3" spread="7.69"/>
                    <measurement group_id="O6" value="166.2" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 12</title>
        <description>The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 12</title>
          <description>The change from baseline is the Week 12 FPG minus the Week 0 fasting plasma glucose (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
          <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 12.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" lower_limit="-2.47" upper_limit="8.00"/>
                    <measurement group_id="O2" value="-18.23" lower_limit="-23.32" upper_limit="-13.14"/>
                    <measurement group_id="O3" value="-23.06" lower_limit="-28.21" upper_limit="-17.90"/>
                    <measurement group_id="O4" value="-31.47" lower_limit="-36.71" upper_limit="-26.24"/>
                    <measurement group_id="O5" value="-29.26" lower_limit="-34.58" upper_limit="-23.94"/>
                    <measurement group_id="O6" value="-17.29" lower_limit="-22.43" upper_limit="-12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-20.99</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.29</ci_lower_limit>
            <ci_upper_limit>-13.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided.P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-25.82</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.17</ci_lower_limit>
            <ci_upper_limit>-18.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-34.23</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.64</ci_lower_limit>
            <ci_upper_limit>-26.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-32.02</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.49</ci_lower_limit>
            <ci_upper_limit>-24.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-20.05</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.39</ci_lower_limit>
            <ci_upper_limit>-12.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 2</title>
        <description>The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
        <time_frame>Baseline and Week 2</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 2</title>
          <description>The change from baseline is the Week 2 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
          <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 2.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.89" lower_limit="0.50" upper_limit="11.27"/>
                    <measurement group_id="O2" value="-15.07" lower_limit="-20.46" upper_limit="-9.69"/>
                    <measurement group_id="O3" value="-15.68" lower_limit="-21.19" upper_limit="-10.17"/>
                    <measurement group_id="O4" value="-26.65" lower_limit="-32.09" upper_limit="-21.21"/>
                    <measurement group_id="O5" value="-16.44" lower_limit="-21.97" upper_limit="-10.91"/>
                    <measurement group_id="O6" value="-14.69" lower_limit="-20.07" upper_limit="-9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-20.96</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.58</ci_lower_limit>
            <ci_upper_limit>-13.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-21.57</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.27</ci_lower_limit>
            <ci_upper_limit>-13.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-32.54</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.20</ci_lower_limit>
            <ci_upper_limit>-24.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-22.33</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.05</ci_lower_limit>
            <ci_upper_limit>-14.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-20.57</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.19</ci_lower_limit>
            <ci_upper_limit>-12.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 4</title>
        <description>The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
        <time_frame>Baseline and Week 4</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 4</title>
          <description>The change from baseline is the Week 4 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
          <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 4.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" lower_limit="0.10" upper_limit="10.24"/>
                    <measurement group_id="O2" value="-16.91" lower_limit="-21.84" upper_limit="-11.99"/>
                    <measurement group_id="O3" value="-22.77" lower_limit="-27.77" upper_limit="-17.78"/>
                    <measurement group_id="O4" value="-27.95" lower_limit="-33.02" upper_limit="-22.88"/>
                    <measurement group_id="O5" value="-26.62" lower_limit="-31.77" upper_limit="-21.46"/>
                    <measurement group_id="O6" value="-18.00" lower_limit="-22.98" upper_limit="-13.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-22.09</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.16</ci_lower_limit>
            <ci_upper_limit>-15.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-27.94</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.06</ci_lower_limit>
            <ci_upper_limit>-20.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-33.12</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.29</ci_lower_limit>
            <ci_upper_limit>-25.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-31.79</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.02</ci_lower_limit>
            <ci_upper_limit>-24.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-23.17</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-30.28</ci_lower_limit>
            <ci_upper_limit>-16.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose at Week 8</title>
        <description>The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 8.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose at Week 8</title>
          <description>The change from baseline is the Week 8 FPG minus the Week 0 FPG (LOCF). Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
          <population>Analysis population included randomized participants who were treated, had a baseline fasting plasma glucose measurement and at least 1 post-baseline fasting plasma glucose measurement up to Week 8.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>80% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="50"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.82" lower_limit="-1.06" upper_limit="8.69"/>
                    <measurement group_id="O2" value="-18.25" lower_limit="-22.99" upper_limit="-13.51"/>
                    <measurement group_id="O3" value="-24.69" lower_limit="-29.49" upper_limit="-19.89"/>
                    <measurement group_id="O4" value="-31.59" lower_limit="-36.46" upper_limit="-26.71"/>
                    <measurement group_id="O5" value="-30.99" lower_limit="-35.94" upper_limit="-26.04"/>
                    <measurement group_id="O6" value="-18.93" lower_limit="-23.71" upper_limit="-14.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-22.07</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.87</ci_lower_limit>
            <ci_upper_limit>-15.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-28.51</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.35</ci_lower_limit>
            <ci_upper_limit>-21.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-35.40</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.30</ci_lower_limit>
            <ci_upper_limit>-28.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-34.81</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.76</ci_lower_limit>
            <ci_upper_limit>-27.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.000</p_value>
            <p_value_desc>P-value is one-sided. P-value is rounded to 3 decimals; therefore, p &lt;0.0005 is reported as 0.000.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with treatment as fixed effect and baseline as covariate with last observation carried forward.</method_desc>
            <param_type>Difference in least squares means</param_type>
            <param_value>-22.75</param_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-29.58</ci_lower_limit>
            <ci_upper_limit>-15.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving HbA1c &lt;7% at Week 12</title>
        <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis population excludes participants with missing Week 12 HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HbA1c &lt;7% at Week 12</title>
          <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
          <population>Analysis population excludes participants with missing Week 12 HbA1c measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="44.0"/>
                    <measurement group_id="O3" value="42.9"/>
                    <measurement group_id="O4" value="38.6"/>
                    <measurement group_id="O5" value="36.2"/>
                    <measurement group_id="O6" value="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving HbA1C &lt;6.5% at Week 12</title>
        <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis population excludes participants with missing Week 12 HbA1c measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving HbA1C &lt;6.5% at Week 12</title>
          <description>Laboratory measurements were performed after an overnight fast ≥8 hours in duration.</description>
          <population>Analysis population excludes participants with missing Week 12 HbA1c measurement.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="44"/>
                <count group_id="O5" value="47"/>
                <count group_id="O6" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="12.0"/>
                    <measurement group_id="O3" value="20.4"/>
                    <measurement group_id="O4" value="13.6"/>
                    <measurement group_id="O5" value="14.9"/>
                    <measurement group_id="O6" value="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Advere Event (AE)</title>
        <description>An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.</description>
        <time_frame>Up to 98 days</time_frame>
        <population>All participants who received at least 1 dose of treatment (including sponsor-supplied metformin).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
          <group group_id="O7">
            <title>Metformin Run-in</title>
            <description>Participants received open-label metformin during the run-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Advere Event (AE)</title>
          <description>An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin.</description>
          <population>All participants who received at least 1 dose of treatment (including sponsor-supplied metformin).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Study Medication Due to an AE</title>
        <description>An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.</description>
        <time_frame>Up to 84 days</time_frame>
        <population>All participants who received at least 1 dose of treatment (including sponsor-supplied metformin).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O2">
            <title>Ertugliflozin 1 mg</title>
            <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O3">
            <title>Ertugliflozin 5 mg</title>
            <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O4">
            <title>Ertugliflozin 10 mg</title>
            <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O5">
            <title>Ertugliflozin 25 mg</title>
            <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
          </group>
          <group group_id="O6">
            <title>Sitagliptin 100 mg</title>
            <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
          </group>
          <group group_id="O7">
            <title>Metformin Run-in</title>
            <description>Participants received open-label metformin during the run-in period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Medication Due to an AE</title>
          <description>An adverse event is defines as any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. Below table includes all data collected since the first dose of sponsor-provided metformin and excludes a temporary discontinuation of study medication.</description>
          <population>All participants who received at least 1 dose of treatment (including sponsor-supplied metformin).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="375"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 weeks (including 10-week run-in period, 12-week treatment period, and 2-week follow-up period).</time_frame>
      <desc>Data presented below include the metformin run-in group (run-in period), 6 treatment groups (treatment period) and no upper limit on the follow-up window for participants who discontinued study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="E2">
          <title>Ertugliflozin 1 mg</title>
          <description>Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="E3">
          <title>Ertugliflozin 5 mg</title>
          <description>Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="E4">
          <title>Ertugliflozin 10 mg</title>
          <description>Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="E5">
          <title>Ertugliflozin 25 mg</title>
          <description>Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days</description>
        </group>
        <group group_id="E6">
          <title>Sitagliptin 100 mg</title>
          <description>Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days</description>
        </group>
        <group group_id="E7">
          <title>Metformin Run-in</title>
          <description>Participants received open-label metformin during the run-in period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E7" events="14" subjects_affected="14" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the Sponsor at least 30-days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

